CannaPharmaRx, Inc. (CPMD) stock
CPMDOTCPharmaceutical PreparationsFiscal year ends December 31
$0.00+0.00 (0.00%)
Close on Oct 16, 2026Market cap $1.36MP/E –Yield –
CannaPharmaRx ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
CannaPharmaRx's ebitda for the twelve months ending Sep 30, 2025 was -$4.05M. For fiscal 2024 it was -$3.63M. The highest annual figure on record is -$954.32K in fiscal 2018.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | -$3.63M | – |
| FY2023 | Dec 31, 2023 | -$1.45M | – |
| FY2022 | Dec 31, 2022 | -$4.92M | – |
| FY2021 | Dec 31, 2021 | -$2.99M | – |
| FY2020 | Dec 31, 2020 | -$14.36M | – |
| FY2019 | Dec 31, 2019 | -$15.85M | – |
| FY2018 | Dec 31, 2018 | -$954.32K | – |
| FY2014 | Dec 31, 2014 | -$3.97M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$360.36K | – |
| Q1 FY2026 | Mar 31, 2026 | -$666.54K | – |
| Q3 FY2025 | Sep 30, 2025 | -$935.65K | – |
| Q2 FY2025 | Jun 30, 2025 | -$840.98K | – |
| Q1 FY2025 | Mar 31, 2025 | -$659.08K | – |
| Q4 FY2024 | Dec 31, 2024 | -$1.62M | -367.6% |
| Q3 FY2024 | Sep 30, 2024 | -$515.98K | – |
| Q2 FY2024 | Jun 30, 2024 | -$453.59K | – |
| Q1 FY2024 | Mar 31, 2024 | -$767.15K | – |
| Q4 FY2023 | Dec 31, 2023 | $603.55K | – |
| Q3 FY2023 | Sep 30, 2023 | -$590.95K | – |
| Q2 FY2023 | Jun 30, 2023 | -$818.98K | – |
| Q1 FY2023 | Mar 31, 2023 | -$714.45K | – |
| Q4 FY2022 | Dec 31, 2022 | -$3.13M | – |
| Q3 FY2022 | Sep 30, 2022 | -$512.50K | – |
| Q2 FY2022 | Jun 30, 2022 | -$632.59K | – |
| Q1 FY2022 | Mar 31, 2022 | -$641.49K | – |
| Q4 FY2021 | Dec 31, 2021 | -$703.78K | – |
| Q3 FY2021 | Sep 30, 2021 | -$770.44K | – |
| Q2 FY2021 | Jun 30, 2021 | -$795.30K | – |
| Q1 FY2021 | Mar 31, 2021 | -$720.94K | – |
| Q4 FY2020 | Dec 31, 2020 | -$9.79M | – |
| Q3 FY2020 | Sep 30, 2020 | -$1.28M | – |
| Q2 FY2020 | Jun 30, 2020 | -$756.01K | – |
| Q1 FY2020 | Mar 31, 2020 | -$2.54M | – |
| Q4 FY2019 | Dec 31, 2019 | -$7.95M | – |
| Q3 FY2019 | Sep 30, 2019 | -$6.32M | – |
| Q2 FY2019 | Jun 30, 2019 | -$657.08K | – |
| Q1 FY2019 | Mar 31, 2019 | -$914.92K | – |
See a number that looks wrong?